Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer.
We report a fatal case of acute pancreatitis which developed in a 76-year-old male with hormone-refractory prostatic carcinoma who was being treated with lanreotide, a slow-release somatostatin analog.
Battaglia
Michele
M
Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. battaglia@urologia.uniba.it
Ditonno
Pasquale
P
Palazzo
Silvano
S
Bettocchi
Carlo
C
Garofalo
Lucio
L
Selvaggi
Francesco Paolo
FP
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D019283:Pancreatitis, Acute Necrotizing / Q000139:chemically induced*; D010456:Peptides, Cyclic / Q000009:adverse effects* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin